The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control their blood glucose level.
During the meeting, the CTAF Panel voted with near unanimity that current evidence is not sufficient to demonstrate a net health benefit associated with use of insulin degludec as compared to insulin glargine U100 (Lantus®, Sanofi-Aventis) for patients with type 1 diabetes and patients with type 2 diabetes using either a basal-only insulin regimen or a basal-bolus regimen. As a result of the Panel’s votes that evidence was insufficient to show a net health benefit, votes on value were not taken during the meeting. ICER’s analyses concluded that the value-based price benchmark for insulin degludec is $7,006 to $7,154 per year. This represents an 8-10% discount from a weighted average cost per year, which is well within the range of typical discounts negotiated by payers.
For questions, contact firstname.lastname@example.org.
Intervention of interest:
- Insulin degludec (Tresiba®, Novo Nordisk A/S).
Below you will find the final documents from the assessment review process: